Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.

British Journal of Cancer
C PacilioNCI-Naples Breast Cancer Group

Abstract

The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m-2 (D) with the combination of docetaxel 80 mg m-2 and epirubicin 75 mg m-2 (ED). The response rate (72 vs 79%), the progression-free survival (median 9 vs 11 months) and the overall survival (median 18 vs 21 months) were not significantly different between the ED (n=26) and D arms (n=25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an anthracycline-based adjuvant or neoadjuvant therapy.

References

Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R FossatiA Liberati
Mar 26, 1999·Journal of Biopharmaceutical Statistics·D Johns, J S Andersen
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S ChanUNKNOWN 303 Study Group
Oct 19, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O PaganiA Goldhirsch
Dec 6, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisV Georgoulias
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vicente Valero, Gabriel N Hortobagyi

❮ Previous
Next ❯

Citations

Nov 19, 2011·Journal of Cancer Research and Clinical Oncology·Maurizio BelfiglioUNKNOWN Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)
Nov 13, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisUNKNOWN Breast Cancer Investigators of the Hellenic Oncology Research Group
Nov 1, 2006·Expert Opinion on Drug Discovery·Janos Nadas, Duxin Sun
Dec 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J TruongK K W Chan
Sep 3, 2010·Nature Reviews. Clinical Oncology·Carlo PalmieriDavid Miles
Nov 19, 2011·International Journal of Clinical Oncology·Ryoichi YanoMikio Masada
Dec 7, 2007·The Oncologist·Alessandro MorabitoUNKNOWN NCI Naples Breast Cancer Group
Jan 5, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Orit FreedmanMark Clemons
Jul 30, 2020·Pharmacology Research & Perspectives·Jeroen J M A HendrikxSerena Marchetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.